论文部分内容阅读
目的观察丹红注射液和环磷腺苷葡胺治疗冠心病不稳定型心绞痛的治疗价值。方法 200例冠心病不稳定型心绞痛患者,随机分为治疗组和对照组,各100例。治疗组给予丹红注射液和环磷腺苷葡胺治疗,对照组给予环磷腺苷葡胺治疗。观察两组临床疗效。结果治疗组心绞痛改善总有效率为92%,高于对照组的84%,但差异无统计学意义(P>0.05);治疗组心电图改善总有效率为94%,高于对照组的85%,差异有统计学意义(P<0.05)。治疗组患者治疗后C反应蛋白(CRP)为(5.24±2.38)mg/L,低于对照组的(6.15±2.19)mg/L;B型尿钠肽(BNP)为(52.90±45.24)pg/ml,低于对照组的(69.70±39.64)pg/ml,差异有统计学意义(P<0.05)。结论丹红注射液和环磷腺苷葡胺治疗冠心病不稳定型心绞痛安全方便,可明显提高临床疗效。
Objective To observe the therapeutic value of Danhong injection and CAMP in the treatment of unstable angina pectoris. Methods 200 cases of coronary heart disease patients with unstable angina were randomly divided into treatment group and control group, each 100 cases. The treatment group was given Danhong injection and cyclic adenosine monophosphate meglumine treatment, the control group was given cyclophosphamide meglumine treatment. The clinical effects of two groups were observed. Results The total effective rate of improvement of angina in treatment group was 92%, which was higher than that in control group (84%), but the difference was not statistically significant (P> 0.05). The total effective rate in treatment group was 94% , The difference was statistically significant (P <0.05). The CRP in the treatment group was (5.24 ± 2.38) mg / L after treatment, which was lower than that in the control group (6.15 ± 2.19) mg / L; The BNP was 52.90 ± 45.24 pg / ml, lower than the control group (69.70 ± 39.64) pg / ml, the difference was statistically significant (P <0.05). Conclusion Danhong injection and amifostine in the treatment of unstable angina pectoris are safe and convenient, and can significantly improve the clinical efficacy.